Stock Analysis·← Pickers

DYN

Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. (DYN) is currently in an uptrend, trading above both the 50-day and 200-day moving averages. RSI is at 68.7, with 3/3 trend checks passing.

Price
$23.99
2026-07-16
Trend score
3/3
Uptrend
RSI (14)
68.7
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

DYN with MA50 and MA200

24.2920.6817.0713.469.8507/3110/2401/2204/1707/15
DYN2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$19.47+23.21% vs price
MA200
$18.45+30.06% vs price
RSI (14)
68.7Neutral zone
MACD Signal
BullishMomentum above signal
Macro Support
$15.87–$16.5631.0% below price · 3 touches
Support Quality
3 touches0.9× zone volume
Chart Summary
Trend summary for DYN

Dyne Therapeutics, Inc. (DYN) is still trading in a constructive trend overall. The latest available price is $23.99, and 3 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 23.2% and above the 200-day moving average by 30.1%.

Momentum and stretch context

DYN currently has an RSI reading of 68.7, which leans mildly positive without looking too stretched. In other words, momentum is supportive, but not yet extreme enough to dominate the entire chart read.

What traders may watch next

For traders reviewing DYN next, the key question is whether the trend still looks healthy or whether price has started to outrun itself. A strong uptrend can stay strong, but entries often become more difficult when price is already extended, so many traders will watch for pullbacks, support reactions, or fresh bases rather than chasing strength blindly.

Company profile

About Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
John G. Cox
Employees
263
Market cap
$3.97B
Beta
1.06
52-week range
$8.63 – $25.00
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
17 Sept 2020
ISIN
US26818M1080
CUSIP
26818M108
Company profile data from Financial Modeling Prep. DYN listed on NASDAQ.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about DYN

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.

DYN Stock Analysis: Uptrend, above MA50 & MA200, RSI 69 | MyStockHarbor